These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Long-term safety and efficacy of topical cyclosporine in 156 children with vernal keratoconjunctivitis. Pucci N; Caputo R; Mori F; De Libero C; Di Grande L; Massai C; Bernardini R; Novembre E Int J Immunopathol Pharmacol; 2010; 23(3):865-71. PubMed ID: 20943058 [TBL] [Abstract][Full Text] [Related]
10. Topical calcineurin inhibitors in the treatment of steroid-dependent atopic keratoconjunctivitis. Tzu JH; Utine CA; Stern ME; Akpek EK Cornea; 2012 Jun; 31(6):649-54. PubMed ID: 22378107 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic Effect of 0.1% Tacrolimus Eye Drops in the Tarsal Form of Vernal Keratoconjunctivitis. Wan Q; Tang J; Han Y; Wang D; Ye H Ophthalmic Res; 2018; 59(3):126-134. PubMed ID: 28803239 [TBL] [Abstract][Full Text] [Related]
12. Topical tacrolimus ointment for treatment of refractory anterior segment inflammatory disorders. Joseph MA; Kaufman HE; Insler M Cornea; 2005 May; 24(4):417-20. PubMed ID: 15829797 [TBL] [Abstract][Full Text] [Related]
13. The efficacy of 0.1% tacrolimus ophthalmic suspension in the treatment of severe atopic keratoconjunctivitis. Yazu H; Shimizu E; Aketa N; Dogru M; Okada N; Fukagawa K; Fujishima H Ann Allergy Asthma Immunol; 2019 Apr; 122(4):387-392.e1. PubMed ID: 30639466 [TBL] [Abstract][Full Text] [Related]
14. Monotherapy of topical tacrolimus 0.03% in the treatment of vernal keratoconjunctivitis in the pediatric population. Samyukta SK; Pawar N; Ravindran M; Allapitchai F; Rengappa R J AAPOS; 2019 Feb; 23(1):36.e1-36.e5. PubMed ID: 30664932 [TBL] [Abstract][Full Text] [Related]
15. Tacrolimus ointment 0.03% for treatment of refractory childhood phlyctenular keratoconjunctivitis. Kymionis GD; Kankariya VP; Kontadakis GA Cornea; 2012 Aug; 31(8):950-2. PubMed ID: 22525784 [TBL] [Abstract][Full Text] [Related]
16. Tacrolimus ointment in the management of atopic keratoconjunctivitis. Benaim D; Tétart F; Bauvin O; Delcampe A; Joly P; Muraine M; Gueudry J J Fr Ophtalmol; 2019 Apr; 42(4):e147-e151. PubMed ID: 30851973 [TBL] [Abstract][Full Text] [Related]
17. Long-Term Safety and Efficacy of Tacrolimus 0.1% in Severe Pediatric Vernal Keratoconjunctivitis. Caputo R; Marziali E; de Libero C; Di Grande L; Danti G; Virgili G; Villani E; Mori F; Bacci GM; Lucenteforte E; Pucci N Cornea; 2021 Nov; 40(11):1395-1401. PubMed ID: 34029239 [TBL] [Abstract][Full Text] [Related]
18. Role of ocular cytology in vernal keratoconjunctivitis. Bruschi G; Ghiglioni DG; Osnaghi S; Rosazza C; Pires Marafon D; Landi M; Marchisio PG Immun Inflamm Dis; 2020 Mar; 8(1):3-7. PubMed ID: 31804769 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of topical 0.05% cyclosporine treatment in children with severe vernal keratoconjunctivitis. Çoban-Karataş M; Özkale Y; Altan-Yaycıoğlu R; Sızmaz S; Pelit A; Metindoğan S; Cantürk-Uğurbaş S; Aydın-Akova Y Turk J Pediatr; 2014; 56(4):410-7. PubMed ID: 25818961 [TBL] [Abstract][Full Text] [Related]
20. Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis. Kiliç A; Gürler B Can J Ophthalmol; 2006 Dec; 41(6):693-8. PubMed ID: 17224949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]